Support for use of MDMA in medical trials and treatment U.S. 2017

Support for use of MDMA in medical trials and treatment U.S. 2017

Percentage of U.S. adults who supported allowing researchers to conduct medical trials with MDMA as of 2017

This statistic shows the percentage of U.S. adults who supported allowing researchers to conduct medical trials with MDMA as of 2017. According to the survey, 61 percent of respondents supported the use of MDMA in medical trials.

Show more

Percentage of U.S. adults who supported allowing researchers to conduct medical trials with MDMA as of 2017

Description

Source

More information

This statistic shows the percentage of U.S. adults who supported allowing researchers to conduct medical trials with MDMA as of 2017. According to the survey, 61 percent of respondents supported the use of MDMA in medical trials.

Show more

Show sources information

As a Premium user you get access to the detailed source references and background information about this statistic.

Show publisher information

Release date

2017

Region

North America, United States

Survey time period

June 2 to 5, 2017

Number of respondents

1,125 respondents

Age group

18 years and older

Special properties

U.S. adults

Supplementary notes

Original question: In 2016, The FDA approved MDMA (also known as ecstasy) for Phase 3 clinical trials as a treatment for post-traumatic stress disorder (PTSD) — a final step before possible approval as a prescription drug. One study showed that with 3 doses of MDMA administered under a psychiatrist's guidance, the patients reported a 56% decrease of severity of symptoms on average. At the end of the study, 66% no longer met the criteria for having PTSD — improvements lasted more than a year after therapy. Do you support or oppose similar medical trials with MDMA being conducted in the future?

Source

Show sources information

As a Premium user you get access to the detailed source references and background information about this statistic.

Show publisher information

Release date

2017

More information

Region

North America, United States

Survey time period

June 2 to 5, 2017

Number of respondents

1,125 respondents

Age group

18 years and older

Special properties

U.S. adults

Supplementary notes

Original question: In 2016, The FDA approved MDMA (also known as ecstasy) for Phase 3 clinical trials as a treatment for post-traumatic stress disorder (PTSD) — a final step before possible approval as a prescription drug. One study showed that with 3 doses of MDMA administered under a psychiatrist's guidance, the patients reported a 56% decrease of severity of symptoms on average. At the end of the study, 66% no longer met the criteria for having PTSD — improvements lasted more than a year after therapy. Do you support or oppose similar medical trials with MDMA being conducted in the future?

This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.

Corporate Account

We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.